淋巴细胞是机体免疫系统最主要的成分。Klein于1960年首先报告它有抗肿瘤活性,Ozd(1961)相继证实带癌机体对自体肿瘤具有抵抗性。这种特异性肿瘤免疫性和移植排斥反应一样,可以而且只能用淋巴细胞传递,血清和抗体则不能。1964年Dezorme第1次应用肿瘤免疫动物的胸导管淋巴细胞使实验肿瘤消退。此后,在探讨输注免疫细胞治疗肿瘤的过程中,人们先后还研究过末梢淋巴细胞、淋巴结细胞、脾细胞、胸腺以及骨髓细胞等。不少病例效果显著。这里仅就淋巴细胞(或白细胞)输注的实验、临床研究情况及有关问题概要地予以介绍。(一)淋巴细胞输注的实验研究 Lymphocytes are the most important components of the body’s immune system. Klein first reported its antitumor activity in 1960, and Ozd (1961) subsequently confirmed that cancerous organisms are resistant to autologous tumors. This specific tumor immunity, like transplant rejection, can and can only be delivered by lymphocytes, while serum and antibodies do not. In 1964, Dezorme’s first application of tumor-immunized thoracic ductal lymphocytes faded experimental tumors. Since then, people have studied the peripheral lymphocytes, lymph node cells, spleen cells, thymus and bone marrow cells in the process of exploring immune cells for the treatment of tumors. Many cases have remarkable effect. Only the lymphocytes (or leukocytes) infusion experiments, clinical studies and related issues outlined. (A) experimental study of lymphocyte infusion